Multiple small- and mid-cap IPOs are scheduled to price and begin trading in mid-October 2026, including Iambic Therapeutics (NASDAQ: IAM) targeting $150 million and City Therapeutics (CTY) at a similar scale, confirming an active window through year-end. Broader pipeline data show 19 new S-1 filings and 24 pricings in the prior 30 days, with biotech and AI-adjacent issuers prominent amid 2026 year-to-date proceeds already exceeding $156 billion. Elevated 10-year Treasury yields near 19-year highs and recent Federal Reserve rate decisions have pressured larger offerings, contributing to postponements and a preference for 2027 among some mega-cap candidates such as OpenAI. Traders are monitoring the October listings and any final prospectuses for high-profile names as key near-term catalysts that could shift implied probabilities for individual company resolutions by December 31.